Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a Phase II, randomized, placebo-controlled, dose-finding trial - Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a Phase II, randomized, placebo-controlled, dose-finding trial - Commentary'. Together they form a unique fingerprint.